Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients

Login or register to view PDF.
Abstract

Abstract

Background
Endocarditis is a common complication in Staphylococcus aureus bacteremia (SAB). We compared risk factors, clinical manifestations, and outcome in a large, prospective cohort of patients with S. aureus endocarditis in injection drug users (IDUs) and in nonaddicts.

Pages

Methods
Four hundred and thirty consecutive adult patients with SAB were prospectively followed up for 3 months. Definite or possible endocarditis by modified Duke criteria was found in 74 patients: 20 patients were IDUs and 54 nonaddicts.

Results
Endocarditis was more common in SAB among drug abusers (46%) than in nonaddicts (14%) (odds ratio [OR], 5.12; 95% confidence interval [CI], 2.65├óÔé¼ÔÇ£9.91; P < 0.001). IDUs were significantly younger (27 ├é┬▒ 15 vs 65 ├é┬▒ 15 years, P < 0.001), had less ultimately or rapidly fatal underlying diseases (0% vs 37%, P < 0.001) or predisposing heart diseases (20% vs 50%, P = 0.03), and their SAB was more often community-acquired (95% vs 39%, P < 0.001). Right-sided endocarditis was observed in 60% of IDUs whereas 93% of nonaddicts had left-sided involvement (P < 0.001). An extracardiac deep infection was found in 85% of IDUs and in 89% of nonaddicts (P = 0.70). Arterial thromboembolic events and severe sepsis were also equally common in both groups. There was no difference in mortality between the groups at 7 days, but at 3 months it was lower among IDUs (10%) compared with nonaddicts (39%) (OR, 5.73; 95% CI, 1.20├óÔé¼ÔÇ£27.25; P = 0.02).

Conclusion
S. aureus endocarditis in IDUs was associated with as high complication rates including extracardiac deep infections, thromboembolic events, or severe sepsis as in nonaddicts. Injection drug abuse in accordance with younger age and lack of underlying diseases were associated with lower mortality, but after adjusting by age and underlying diseases injection drug abuse was not significantly associated with mortality.

Background
Bacteremic infections caused by Staphylococcus aureus have been reported with increasing frequency, and it has emerged as a leading cause of infective endocarditis (IE) in many regions of the world [1-3]. Endocarditis has been observed in 11% to 35% of S. aureus bacteremias (SAB) attributable to different sets of diagnostic criteria [4-6]. S. aureus endocarditis is associated with higher occurrence of extracardiac deep infections due to metastatic spread, thromboembolic complications, and a high mortality compared with IE caused by other pathogens [1,2].

The incidence of endocarditis has not been changed during the past two decades [7,8] but classic risk factors such as rheumatic heart disease are being replaced by new groups, including injection drug users (IDUs), elderly patients with degenerative valve disease, patients with intravascular catheter or prosthetic valve, and nosocomial acquisition [2,3,8]. One of the reasons for increased incidence of S. aureus in IE is injection drug abuse [9-11]. Colonization with S. aureus, HIV-related immunosuppression, female sex, increasing injection drug use frequency, and a history of previous IE are associated with a higher risk for endocarditis [11,12].

Pages

References
  1. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VGJ: Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005, 41:507-514.
  2. Fowler VGJ, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS: Staphylococcus aureus endocarditis: a consequence of medical progress. Jama 2005, 293:3012-3021.
  3. Mylonakis E, Calderwood SB: Infective endocarditis in adults. N Engl J Med 2001, 345:1318-1330.
  4. Mirimanoff RO, Glauser MP: Endocarditis during Staphylococcus aureus septicemia in a population of non-drug addicts. Arch Intern Med 1982, 142:1311-1313.
  5. Hedstrom SA, Christensson B: Staphylococcus aureus septicaemia and endocarditis at the University Hospital in Lund 1976-1980. Scand J Infect Dis Suppl 1983, 41:38-48.
  6. Chang FY, MacDonald BB, Peacock JEJ, Musher DM, Triplett P, Mylotte JM, O'Donnell A, Wagener MM, Yu VL: A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003, 82:322-332.
  7. Cecchi E, Forno D, Imazio M, Migliardi A, Gnavi R, Dal Conte I, Trinchero R: New trends in the epidemiological and clinical features of infective endocarditis: results of a multicenter prospective study. Ital Heart J 2004, 5:249-256.
  8. Moreillon P, Que YA: Infective endocarditis. Lancet 2004, 363:139-149.
  9. Bassetti S, Battegay M: Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection 2004, 32:163-169.
  10. Mathew J, Addai T, Anand A, Morrobel A, Maheshwari P, Freels S: Clinical features, site of involvement, bacteriologic findings, and outcome of infective endocarditis in intravenous drug users. Arch Intern Med 1995, 155:1641-1648.
  11. Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D: Prospective study of infective endocarditis among injection drug users. J Infect Dis 2002, 185:1761-1766.
  12. Gordon RJ, Lowy FD: Bacterial infections in drug users. N Engl J Med 2005, 353:1945-1954.
  13. Chambers HF, Korzeniowski OM, Sande MA: Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore) 1983, 62:170-177.
  14. Julander I: Unfavourable prognostic factors in Staphylococcus aureus septicemia and endocarditis. Scand J Infect Dis 1985, 17:179-187.
  15. Karchmer AW: Infective endocarditis. In Heart Disease: A Textbook of Cardiovascular Medicine. 6th edition. Edited by: Braunwald E, Zipes DP, Libby P. WB Saunders Company: Philadelphia; 2001:1723-1750.
  16. Miro JM, del Rio A, Mestres CA: Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. Cardiol Clin 2003, 21:167-84, v-vi.
  17. Torres-Tortosa M, de Cueto M, Vergara A, Sanchez-Porto A, Perez-Guzman E, Gonzalez-Serrano M, Canueto J: Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cadiz. Eur J Clin Microbiol Infect Dis 1994, 13:559-564.
  18. Hart RG, Foster JW, Luther MF, Kanter MC: Stroke in infective endocarditis. Stroke 1990, 21:695-700.
  19. Watanakunakorn C: Staphylococcus aureus endocarditis at a community teaching hospital, 1980 to 1991. An analysis of 106 cases. Arch Intern Med 1994, 154:2330-2335.
  20. Ruotsalainen E, Järvinen A, Koivula I, Kauma H, Rintala E, Lumio J, Kotilainen P, Vaara M, Nikoskelainen J, Valtonen V: Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 2006, 259:179-190.
  21. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VGJ, Ryan T, Bashore T, Corey GR: Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000, 30:633-638.
  22. McCabe WR, Jackson GG: Gram negative bacteraemia 1. Etiology and ecology. Arch Intern Med 1962, 110:847-855.
  23. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256.
  24. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE: Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32:1249-1272.
  25. Fowler VGJ, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, Cheng AC, Dudley T, Oddone EZ: Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003, 163:2066-2072.
  26. Levine DP, Crane LR, Zervos MJ: Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. Rev Infect Dis 1986, 8:374-396.
  27. Moss R, Munt B: Injection drug use and right sided endocarditis. Heart 2003, 89:577-581.
  28. Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Shamse Tabriz M, Sharma M, Saeed S: Persistence in Staphylococcus aureus bacteremia: Incidence, characteristics of patients and outcome. Scand J Infect Dis 2006, 38:7-14.
  29. Mylotte JM, Tayara A: Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000, 31:1170-1174.
  30. Julander I: Staphylococcal septicaemia and endocarditis in 80 drug addicts. Aspects on epidemiology, clinical and laboratory findings and prognosis. Scand J Infect Dis Suppl 1983, 41:49-55.
  31. Graves MK, Soto L: Left-sided endocarditis in parenteral drug abusers: recent experience at a large community hospital. South Med J 1992, 85:378-380.
  32. Bayer AS, Lam K, Ginzton L, Norman DC, Chiu CY, Ward JI: Staphylococcus aureus bacteremia. Clinical, serologic, and echocardiographic findings in patients with and without endocarditis. Arch Intern Med 1987, 147:457-462.
  33. Fowler VGJ, Schelenz S, Bayer AS: Endocarditis and intravascular infections. In Mandell, Douglas and Bennett`s Principles and Practice of Infectious Diseases. Volume 2. 6th edition. Edited by: Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone; 2005:975-1021.
  34. Fowler VGJ, Sanders LL, Kong LK, McClelland RS, Gottlieb GS, Li J, Ryan T, Sexton DJ, Roussakis G, Harrell LJ, Corey GR: Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999, 28:106-114.
  35. Ringberg H, Thoren A, Lilja B: Metastatic complications of Staphylococcus aureus septicemia. To seek is to find. Infection 2000, 28:132-136.
  36. Baddour LM, Bisno AL: Infective endocarditis complicating mitral valve prolapse: epidemiologic, clinical, and microbiologic aspects. Rev Infect Dis 1986, 8:117-137.
  37. Fabri JJ, Issa VS, Pomerantzeff PM, Grinberg M, Barretto AC, Mansur AJ: Time-related distribution, risk factors and prognostic influence of embolism in patients with left-sided infective endocarditis. Int J Cardiol 2006, 110:334-339.
  38. Hasbun R, Vikram HR, Barakat LA, Buenconsejo J, Quagliarello VJ: Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA 2003, 289:1933-1940.
  39. Thuny F, Disalvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, Casalta JP, Gouvernet J, Derumeaux G, Iarussi D, Ambrosi P, Calabro R, Riberi A, Collart F, Metras D, Lepidi H, Raoult D, Harle JR, Weiller PJ, Cohen A, Habib G: Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 2005, 112:69-75.
  40. Hecht SR, Berger M: Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med 1992, 117:560-566.
  41. Bouza E, Menasalvas A, Munoz P, Vasallo FJ, del Mar Moreno M, Garcia Fernandez MA: Infective endocarditis-a prospective study at the end of the twentieth century: new predisposing conditions, new etiologic agents, and still a high mortality. Medicine (Baltimore) 2001, 80:298-307.
  42. Sklaver AR, Hoffman TA, Greenman RL: Staphylococcal endocarditis in addicts. South Med J 1978, 71:638-643.
  43. Faber M, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl V: Staphylococcus aureus endocarditis in Danish intravenous drug users: high proportion of left-sided endocarditis. Scand J Infect Dis 1995, 27:483-487.
  44. Arbulu A, Holmes RJ, Asfaw I: Surgical treatment of intractable right-sided infective endocarditis in drug addicts: 25 years experience. J Heart Valve Dis 1993, 2:129-37; discussion 138-9.
  45. Baddour LM, Wilson WR, Bayer AS, Fowler VGJ, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA: Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-434.
  46. Moreillon P, Que YA, Glauser MP: Staphylococcus aureus (including staphylococcal toxic shock). In Mandell, Douglas, and Bennett`s Principles and Practice of Infectious Diseases. Volume 2. 6th edition. Edited by: Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone; 2005:2321-2351.
  47. Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
  48. Petti CA, Fowler VGJ: Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am 2002, 16:413-435.
  49. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C: Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996, 101:68-76.
  50. Dworkin RJ, Lee BL, Sande MA, Chambers HF: Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989, 2:1071-1073.